JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
SOUTH SAN FRANCISCO - Twist Bioscience Corporation (NASDAQ:TWST), a synthetic DNA tools developer with a market capitalization of $1.66 billion and strong liquidity position, announced Wednesday the appointment of Trynka Shineman Blake to its board of directors, where she will also serve on the audit committee. According to InvestingPro data, the company maintains a healthy current ratio of 3.9x, with cash reserves exceeding its debt obligations.
Shineman Blake previously served as chief executive officer of Vistaprint, a Cimpress company, where she helped scale the business from under $100 million to more than $1 billion in revenue during her tenure. Before her role as CEO, she held various leadership positions at Vistaprint including president of North America, executive vice president of global marketing, and chief customer officer.
"Trynka is an accomplished global leader with a proven track record of driving profitable growth and innovation of custom products at scale," said Emily M. Leproust, CEO and co-founder of Twist Bioscience, in a press release statement.
Shineman Blake brings nearly three decades of experience across corporate governance, customer experience, digital transformation, and global marketing. Prior to Vistaprint, she held senior positions at PreVision Marketing, which was later acquired by Valassis. The appointment comes at a crucial time for Twist Bioscience, as InvestingPro analysis shows the stock trading near its 52-week low of $27.12, having declined approximately 49% over the past six months.
She currently serves on the boards of several public and private companies, including Tripadvisor, Semrush, Captura, and Steer. Her previous board experience includes Ally Financial Inc., UBM PLC, and the Management Board of Vistaprint.
Shineman Blake holds a B.A. in psychology from Cornell University and an M.B.A. from Columbia Business School.
Twist Bioscience, which develops synthetic DNA tools for customers in medicine, agriculture, and industrial chemicals, is approaching an adjusted EBITDA breakeven point according to the company’s statement. While the company posted revenue growth of 23% in the last twelve months, reaching $362 million, InvestingPro analysis reveals multiple additional insights about the company’s financial health and market position. For detailed analysis and 12 more exclusive ProTips, including vital profitability metrics and growth forecasts, investors can access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Twist Bioscience reported a notable 18% increase in revenue for Q3 2025, reaching $96.1 million. Despite this positive revenue growth, the company posted an adjusted EBITDA loss of $8 million, which marked an improvement from the previous fiscal year. Meanwhile, JPMorgan has adjusted its price target for Twist Bioscience to $25, maintaining an Underweight rating. TD Cowen also revised its price target, lowering it to $36 while keeping a Buy rating, citing changes in fiscal year 2025 guidance due to a key customer’s transition from clinical to commercial stage. Evercore ISI reduced its price target to $46, highlighting strong performance in the next-generation sequencing segment and solid gross margins. These developments reflect a mixed sentiment among analysts, with varying expectations for the company’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.